Exploratory pilot study of exogenous sustained-release melatonin on nocturia in Parkinson's disease.

Amit BatlaSara SimeoniTomoyuki UchiyamaLorenzo deMinJoanne BaldwinCharles MelbourneSaiful IslamKailash P BhatiaMahreen PakzadSofia ErikssonJalesh N Panicker

Published in: European journal of neurology (2021)

In this preliminary open-label study, administration of sustained-release melatonin 2 mg was found to be safe for clinical use and was associated with significant improvements in night-time frequency and nocturnal voided volumes in PD patients.

Keyphrases

end stage renal disease
open label
ejection fraction
newly diagnosed
chronic kidney disease
blood pressure
clinical trial
prognostic factors
peritoneal dialysis
randomized controlled trial
physical activity
depressive symptoms
phase iii
rectal cancer